Libertatem Magazine Issue 1 | Page 42

Commission Competition Act, 2002 has overriding effect over other legislations for the time being in force.” In the same case, FICCI filed information against United Producers/Distributors Forum (UPDF) and others for market cartel in films against the Multiplexes. In order to raise their revenue, UPDF had refused to deal with multiplex owners. The fact that multiplex business is 100 percent dependent upon films hence, making this deal to come into the category of refusal to deal and anticompetitive. The UPDF and others hold almost 100 percent share in Bollywood film industry. UPDF had been indulged in limiting and controlling supply of films in the market by refusal to deal with Multiplexes which is the violation of Section 3(3) of Competition Act 2002. CCI prima facie found there is anticompetitive agreement and there is abuse of dominant position also. So CCI directed Director General (DG) to inquire into the matter. DG inquired into the matter and reported it to be cartel. CCI issued a show cause notice. UPDF instead of answering to show-cause notice, the complainant approached the Bombay High Court. UPDF contended that films are subject to copyright protection. Therefore Copyright board has the jurisdiction to deal with matter. Furthermore, contended that for exclusive license, only remedy is compulsory license available under Copyright Act. So petitioner challenges the action taken by the CCI on the ground of lack of jurisdiction. Though, the issue was discussed earlier in Kingfisher v. Competition Commission of India. Considering the importance of the matter, Bombay High Court discussed the matter in great detail. The court ruled Section 3(5) does not restrict the right of any person to sue for infringement of patent, copyright, trademark etc. All the defences which can be raised before copyright board can also be raised before CCI. Hence the competition law does not bar application of other laws. Thus the TRIPs Agreement provides a basic framework of intellectual property protection as well as enforcement of anticompetitive licensing practices in intellectual property. The IPRs and competition law objectives are consistent and compatible where the competition law intervention is required only when there is an abuse of monopoly rights. It is important to notice that more than 100 countries have enacted competition laws and at the time more than 159 countries have IP laws, and both enforcing authorities must have a role in IP and competition law policy making, especially in developing countries. Moreover the conflict and the struggle over these two issues have created a hazardous situation in the pharmaceutical industry. Thus, there is a great need for guidance in the legislative framework to suit the nature of developing nations particularly for India.